ADRXADARx Pharmaceuticals, Inc.
20.09USD+3.82%Mkt Cap: —P/E: —1d ago
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including …
Industry Peers
Biotechnology$133.74BUSDP/E 30.8
$78.76BUSD
$77.45BUSDP/E 18.6
$60.46BUSDP/E 37.0
$57.09BUSDP/E 36.6
$44.04BUSDP/E 18.8
$43.24BUSD
$41.52BUSDP/E 65.7
$34.17BUSDP/E 44.6
$33.73BUSDP/E 31.4
$26.71BUSD
$25.70BUSD
$25.30BUSDP/E 15.9
$24.89BUSD
$21.74BUSDP/E 28.1
$20.62BUSDP/E 27.7
$15.47BUSDP/E 16.3
$15.13BUSDP/E 18.1
$14.46BUSDP/E 18.4
$13.02BUSD
Key Statistics
Company
Market Cap—
Enterprise Value2.00B $
Revenue (TTM)6.13M $
Gross Profit-83.74M $
Net Income (TTM)-73.09M $
Revenue/Share0.5400 USD
Last Price20.09 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-19.02
EV/Revenue326.34
P/S—
P/B-0.87
EPS (TTM)—
EPS (Forward)—
52W Range
18.5034% of range23.21
52W High23.21 USD
52W Low18.50 USD
Profitability
Gross Margin0.00%
Oper. Margin-4006.84%
EBITDA Margin0.00%
Profit Margin-2119.11%
ROE36.14%
ROA-14.40%
Growth
Revenue Growth258.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF262.29M $
CapEx (TTM)2.94M $
FCF Margin—
FCF Yield—
Net Debt-420.35M $
Net Debt/EBITDA4.00
Balance Sheet
Debt/Equity-0.04
Current Ratio12.98
Quick Ratio12.56
Book Value/Sh-22.1580 USD
Cash/Share4.009 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float—
Insiders—
Institutions—
Technical
SMA 5019.35 (+3.8%)
SMA 20019.35 (+3.8%)
Beta—
S&P 52W Chg16.25%
Avg Vol (30d)2.71M
Avg Vol (10d)4.21M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—